Les anticorps monoclonaux dans les maladies immunes inflammatoires chroniques

Luca Semerano; Marie-Christophe Boissier

doi:10.1051/medsci/200925121108

Accueil

Tous les numéros

Volume 25 / Numéro 12 (Décembre 2009)

Med Sci (Paris), 25 12 (2009) 1108-1112

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 25, Numéro 12, Décembre 2009 Anticorps monoclonaux en thérapeutique


Page(s)		1108 - 1112
Section		II - La réalité clinique
DOI		https://doi.org/10.1051/medsci/200925121108
Publié en ligne		15 décembre 2009

Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312 : 724–9. [Google Scholar]
Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin 1. Purification of two immunoogically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 1985; 162 : 1208–22. [Google Scholar]
Henderson B, Pettifer ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989; 75 : 306–10. [Google Scholar]
Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36 : 1681–90. [Google Scholar]
Vital EM, Emery P. The development of targeted therapies in rheumatoid arthritis. J Autoimmunity 2008; 31 : 219–27. [Google Scholar]
Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223 : 7–19. [Google Scholar]
Brennan F, Mc Innes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118 : 3537–45. [Google Scholar]
Boissier MC, Assier E, Falgarone G, et al. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 2008; 75 : 373–5. [Google Scholar]
Scheinecker C, Redlich K, Smolen J. Cytokines as therapeutic targets: advances and limitations. Immunity 2008; 28 : 440–4. [Google Scholar]
Launois R, Payet S, Saidenberg-Kermanac’h N, et al. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008; 75 : 688–95. [Google Scholar]
Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis 2009 (sous presse). [Google Scholar]
Ranganathan P. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents. Curr Opin Mol Ther 2008; 10 : 562–7. [Google Scholar]
Delavallée L, Le Buanec H, Bessis N, et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008; 67 : 1332–8. [Google Scholar]
Gallois A, Mazzorana M, Vacher J, Jurdic P. Ostéo-immunologie : une vision globale et intégrée du tissu squelettique et du sytème immunitaire. Med Sci (Paris) 2009; 25 : 259–65. [Google Scholar]
Bensussan A, Bizzini B, Pouletty P, et al. Les kinoïdes : Une nouvelle génération de vaccins thérapeutiques. Med Sci (Paris) 2008; 24 : 306–13. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312 : 724–9. [Google Scholar]

[2] Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin 1. Purification of two immunoogically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 1985; 162 : 1208–22. [Google Scholar]

[3] Henderson B, Pettifer ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989; 75 : 306–10. [Google Scholar]

[4] Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36 : 1681–90. [Google Scholar]

[5] Vital EM, Emery P. The development of targeted therapies in rheumatoid arthritis. J Autoimmunity 2008; 31 : 219–27. [Google Scholar]

[6] Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223 : 7–19. [Google Scholar]

[7] Brennan F, Mc Innes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118 : 3537–45. [Google Scholar]

[8] Boissier MC, Assier E, Falgarone G, et al. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 2008; 75 : 373–5. [Google Scholar]

[9] Scheinecker C, Redlich K, Smolen J. Cytokines as therapeutic targets: advances and limitations. Immunity 2008; 28 : 440–4. [Google Scholar]

[10] Launois R, Payet S, Saidenberg-Kermanac’h N, et al. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008; 75 : 688–95. [Google Scholar]

[11] Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis 2009 (sous presse). [Google Scholar]

[12] Ranganathan P. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents. Curr Opin Mol Ther 2008; 10 : 562–7. [Google Scholar]

[13] Delavallée L, Le Buanec H, Bessis N, et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008; 67 : 1332–8. [Google Scholar]

[14] Gallois A, Mazzorana M, Vacher J, Jurdic P. Ostéo-immunologie : une vision globale et intégrée du tissu squelettique et du sytème immunitaire. Med Sci (Paris) 2009; 25 : 259–65. [Google Scholar]

[15] Bensussan A, Bizzini B, Pouletty P, et al. Les kinoïdes : Une nouvelle génération de vaccins thérapeutiques. Med Sci (Paris) 2008; 24 : 306–13. [Google Scholar]